Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 5

Fludarabine in the treatment of chronic lymphocytic leukemia: a review

Authors Francesca Ricci, Alessandra Tedeschi, Enrica Morra, Marco Montillo

Published Date March 2009 Volume 2009:5 Pages 187—207

DOI http://dx.doi.org/10.2147/TCRM.S3688

Published 4 March 2009

Francesca Ricci, Alessandra Tedeschi, Enrica Morra, Marco Montillo

Department of Oncology/Haematology, Niguarda Ca’Granda Hospital, Milan, Italy

Abstract: Fludarabine (FAMP) is the most effective and most extensively studied purine analog in indolent B-cell malignancies. Its use is indicated for first- and second-line treatment of B-cell chronic lymphocytic leukemia (B-CLL). FAMP as a single agent has produced superior response rates and progression-free survival than standard therapy with chlorambucil and alkylator-based regimen. Efficacy of FAMP may be increased by combining this purine analog with other chemotherapeutic and non-chemotherapeutic agents. FAMP and cyclophosphamide combination (FC) has shown promising results with higher overall response and complete response rates than FAMP in monotherapy, although no difference has been detected in survival. Quality of response and eradication of minimal residual disease (MRD) have been reported to be associated with prolonged survival. Eradication of MRD has been achieved by combining FC with mitoxantrone or monoclonal antibody including alemtuzumab or rituximab or both. FAMP has been widely used in non-myeloablative conditioning regimens, often combined with a variety of other cytotoxic agents, with the aim of inducing enough immunosuppression to allow successful engraftment and to exert some pretransplant anti-tumor activity. The current paper provides an overview of use of FAMP as a single agent or as a cornerstone of different therapeutic strategies for treatment of B-CLL patients.

Keywords: fludarabine, chronic lymphocytic leukemia, cyclophosphamide

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

The spectrum of use of rituximab in chronic lymphocytic leukemia

Alessandra Tedeschi, Eleonora Vismara, Francesca Ricci, et al

OncoTargets and Therapy 2010, 3:227-246

Published Date: 26 November 2010

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)

Marco Montillo, Francesca Ricci, Sara Miqueleiz, Alessandra Tedeschi, Enrica Morra

Biologics: Targets and Therapy 2008, 2:41-52

Published Date: 25 March 2008

Readers of this article also read:

Characterization and evolution of dermal filaments from patients with Morgellons disease

Middelveen MJ, Mayne PJ, Kahn DG, Stricker RB

Clinical, Cosmetic and Investigational Dermatology 2013, 6:1-21

Published Date: 8 January 2013

Insight into 144 patients with ocular vascular events during VEGF antagonist injections

Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz SG

Clinical Ophthalmology 2012, 6:343-363

Published Date: 6 March 2012

Effect of vascular burden as measured by vascular indexes upon vascular dementia: a matched case-control study

Takahashi PY, Caldwell CR, Targonski PV

Clinical Interventions in Aging 2012, 7:27-33

Published Date: 18 January 2012

Filament formation associated with spirochetal infection: a comparative approach to Morgellons disease

Middelveen MJ, Stricker RB

Clinical, Cosmetic and Investigational Dermatology 2011, 4:167-177

Published Date: 14 November 2011

Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer

Chauhan A, Zubair S, Tufail S, Sherwani A, Sajid M, Raman SC, Azam A, Owais M

International Journal of Nanomedicine 2011, 6:2305-2319

Published Date: 12 October 2011

Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease

Mannu P, Rinaldi S, Fontani V, Castagna A

Clinical Interventions in Aging 2011, 6:207-211

Published Date: 26 July 2011

Dietary habits and cardiovascular disease risk in middle-aged and elderly populations: a review of evidence

Eleni Tourlouki, Antonia-Leda Matalas, Demosthenes B Panagiotakos

Clinical Interventions in Aging 2009, 4:319-330

Published Date: 14 July 2009

Eggshell membrane: A possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies

Kevin J Ruff, Dale P DeVore, Michael D Leu, Mark A Robinson

Clinical Interventions in Aging 2009, 4:235-240

Published Date: 18 May 2009

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses

Hideki Hasegawa, Takeshi Ichinohe, Akira Ainai, Shin-ichi Tamura, Takeshi Kurata

Therapeutics and Clinical Risk Management 2009, 5:125-132

Published Date: 9 March 2009

Wine consumers’ environmental knowledge and attitudes: Influence on willingness to purchase

Nelson Barber, Christopher Taylor, Sandy Strick

International Journal of Wine Research 2009, 1:59-72

Published Date: 9 February 2009